Evidence map›Paper›PMID 37601038›Full record

ArticleTherapeutic advances in chronic disease2023

Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.

Saskia Inniss, Konstantinos C Fragkos, Lisa Whitley, Rachel Wimpory, Eleanor Rebello, Ana Lisboa, Tanvi Khetan, Jasmine Hassan, Kate Simpson, Anisha Bhagwanani and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in chronic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Saskia InnissGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-2978-7236
Konstantinos C FragkosGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Lisa WhitleyGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Rachel WimporyGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Eleanor RebelloGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Ana LisboaGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Tanvi KhetanUCL Medical School, University College London, London, UK.
Jasmine HassanUCL Medical School, University College London, London, UK.
Kate SimpsonDivision of Medicine, University College London, London, UK.
Anisha BhagwananiGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Roser VegaGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Ioanna ParisiGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Paul HarrowGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Edward SewardGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Sara McCartneyGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Stuart BloomGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Andrew M SmithEastman Dental Institute, University College London, London, UK.
Andrew PlumbGastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK.
Farooq Z RahmanGastrointestinal Services, University College London Hospitals NHS Foundation Trust, Ground Floor West, 250 Euston Road, London, NW1 2PG, UK.
University College London Hospitals NHS Foundation Trust · GBUniversity College Hospital · GBEastman Dental Hospital · GBUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ustekinumab was approved in 2016 for the treatment of moderate-severe Crohn's disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use imaging techniques to predict response to biologics in CD. Objectives: We assessed the 2-year real-world effectiveness and safety of ustekinumab in a tertiary CD cohort with the use of novel imaging techniques. Design: Retrospective cohort study. Methods: Retrospective data were collected between 2016 and 2021. Study end points included ustekinumab persistence, biological and/or clinical response and remission at 12, 18 and 24 months. Statistical analysis included demographic and inferential analyses. Results: In all, 131 CD patients [57.3% female, median age of 26.0 (21.0-37.0)] were included. Patients were non-bio naïve, and the majority received ustekinumab as third- or fourth-line treatment. At 24 months, 61.0% (80/131) persisted with ustekinumab [52.7% (69/131) steroid free]. Clinical response was reported in 55.2% (37/67), clinical remission in 85.7% (57/67), biological response in 46.8% (22/47) and biological remission in 31.9% (15/47) of patients at 24 months. The low outcome numbers were attributable to missing data. Improvements in routine disease markers, including C-reactive protein and Harvey-Bradshaw Index, were also reflected in magnetic resonance imaging-derived disease scores. The presence of penetrating CD, an -ostomy and sarcopenia were all predictors of poorer ustekinumab outcomes ( Conclusion: Ustekinumab is effective in non-bio-naïve CD patients with non-stricturing, non-penetrating disease with an unremarkable safety profile but may be less effective in those with penetrating disease, -ostomies and sarcopenia.

Indexed as

Crohn’s diseasepersistencesarcopeniaustekinumab

Identifiers

PMID37601038
PMCPMC10434845
OpenAlexW4385883901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.